2-piperidone has been researched along with Adverse Drug Event in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chopra, R; DiMartino, J; Gandhi, AK; Hagner, PR; Hege, K; Li, Y; Papadopoulos, KP; Pourdehnad, M; Rasco, DW; Shih, K; Wei, X | 1 |
| Fireman, BH; Friedman, GD; Selby, JV | 1 |
1 trial(s) available for 2-piperidone and Adverse Drug Event
| Article | Year |
|---|---|
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Piperidones; Quinazolinones; Ubiquitin-Protein Ligases | 2019 |
1 other study(ies) available for 2-piperidone and Adverse Drug Event
| Article | Year |
|---|---|
Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up.
Topics: Anti-Bacterial Agents; Atropa belladonna; Carcinogens; Drug-Related Side Effects and Adverse Reactions; Erythromycin; Esophageal Neoplasms; Folic Acid; Follow-Up Studies; Gastrointestinal Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neomycin; Neoplasms; Phenylbutazone; Piperidones; Plants, Medicinal; Plants, Toxic; Polymyxin B; Propantheline; Secobarbital; Sulfathiazoles; Vitamins | 1989 |